Halozyme Secures Preliminary Injunction Against Merck & Co. in Keytruda Patent Dispute

Halozyme has been granted a preliminary injunction against Merck & Co. in Germany, preventing the distribution of Keytruda SC due to patent infringement. The ruling applies only to the subcutaneous formulation, not the intravenous one. Merck & Co. disagrees with the ruling and believes its patent is invalid globally. The case is ongoing in both Germany and the US.